The stress granule/LLPS hypothesis is important because it identifies new directions for therapeutic intervention for tauopathies and other neurodegenerative diseases. Dr. Wolozin has developed methods to analyze the pathological RNA granules and stress granules that accumulate in brain diseases. He has also developed a series of compounds that potently and effectively inhibit TDP-43 aggregation in multiple neuronal models. In 2014, Dr. Wolozin combined forces with Glenn Larsen, Ph.D. to co-found the biotechnology company, Aquinnah Pharmaceuticals. Aquinnah Pharmaceuticals Inc. is dedicated to developing novel medicines to treat neurodegenerative diseases, and using a technology platform that focuses on the roles of RNA binding proteins, RNA metabolism and stress granules in neurodegenerative diseases.
